Panoramica dell'azienda
Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical entity focused on the development of orally bioavailable small molecule therapeutic products designed to treat conditions such as cancer, liver inflammatory diseases, and erectile dysfunction within the Israeli market. The company functions within the broader Healthcare sector, specifically the Biotechnology industry, which typically involves significant research and development expenditures to bring novel compounds to market before achieving commercial viability. Currently, the organization employs five individuals to drive its operational activities and strategic initiatives related to drug candidate progression. With a total market capitalization of $6.85M and annual revenue of $405,000, the firm presents the profile of a micro-cap entity with extremely limited scale relative to established pharmaceutical peers. These valuation and revenue figures indicate that the company is in a pre-commercial or early-stage phase where its primary focus remains on advancing its lead drug candidate, Piclidenoson, rather than generating substantial commercial cash flows or establishing a broad market presence.
Salute finanziaria
The company reported revenue of $405,000 over the trailing twelve-month period, yet recorded a net income of $-9,828,000 and an EBITDA of $-9,926,000, highlighting a substantial negative gap between top-line generation and profitability. This disparity reveals a cost structure dominated by high operating expenses, likely driven by research and development costs, which consume nearly 2,500% of the reported revenue before reaching the bottom line. Free cash flow stands at $-4,985,750, indicating that the company is burning through its liquidity reserves to fund its clinical pipeline and operational overhead. Despite these outflows, the balance sheet maintains a cash position of $8.54M against a relatively modest debt load of $71,000, suggesting a specific liquidity buffer intended to sustain operations through extended development cycles. The debt-to-equity ratio of 1.27 reflects a capital structure where debt levels are significant relative to equity, yet the substantial cash holding provides a safety net against immediate solvency risks. Short-term liquidity appears robust, as evidenced by a current ratio of 3.46, which implies the company holds sufficient current assets to cover its current liabilities more than three times over. Return on Equity is reported at -178.2% and Return on Assets at -66.7%, metrics that negatively reflect the current stage of the business where investment returns are eroded by heavy expenditure rather than generated by commercial sales.
Valutazione del valore
Valuation metrics for the company present a complex picture due to the lack of profitable operations, with a trailing P/E Ratio (TTM) listed as N/A and a forward P/E of -4.00. The absence of a trailing P/E ratio combined with a negative forward multiple implies that analysts cannot value the stock based on current earnings power and must rely on alternative metrics or potential future earnings assumptions. The price-to-book ratio stands at 0.68, indicating that the market currently values the company's equity at approximately 68% of its book value, which suggests the market is pricing in significant risks regarding the commercialization of its drug pipeline. Additionally, the price-to-sales ratio is 16.92 and the EV/EBITDA is -0.41, figures that suggest the market is paying a high multiple for revenue given the lack of profitability, a common characteristic of early-stage biotechnology firms betting on future milestones. The stock's trading range over the past year has fluctuated between a 52-week high of $36.40 and a 52-week low of $2.90, illustrating extreme volatility inherent in small-cap biotech equities. The beta value of -0.10 is unique, as it indicates an inverse relationship with the broader market, meaning the stock tends to move in the opposite direction of the general market index during periods of standard market correlation.
Growth & Income
Revenue growth year-over-year is recorded at -43.3%, while earnings growth is N/A due to the absence of positive net income in the prior comparative period. The negative revenue growth indicates a contraction in sales, which could stem from the cessation of sales for previous product lines or a lack of commercialization activity while the lead candidate, Piclidenoson, remains in clinical development. Since the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, all available earnings and cash flow are theoretically available for reinvestment, though in this case, the company is primarily consuming cash for R&D. The overall growth and income profile is characterized by negative revenue expansion and a complete absence of dividend income, positioning the investment as a pure bet on the future success of the clinical-stage assets rather than current financial performance or income generation.